Cargando…

Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults

Chagas disease (ChD), caused by Trypanosoma cruzi, has a global prevalence due to patient migration. However, despite its worldwide distribution, long-term follow-up efficacy studies with nifurtimox (NF) are scarce and have been conducted with only small numbers of patients. A retrospective study of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falk, N., Berenstein, A. J., Moscatelli, G., Moroni, S., González, N., Ballering, G., Freilij, H., Altcheh, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112880/ https://www.ncbi.nlm.nih.gov/pubmed/35416710 http://dx.doi.org/10.1128/aac.02021-21

Ejemplares similares

Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
por: Moroni, Samanta, et al.
Publicado: (2019)

Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE)
por: Altcheh, Jaime, et al.
Publicado: (2023)

Prevention of congenital Chagas through treatment of girls and women of childbearing age
por: Moscatelli, Guillermo, et al.
Publicado: (2015)

Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study
por: González, Nicolás Leonel, et al.
Publicado: (2022)

Longitudinal follow up of serological response in children treated for Chagas disease
por: Moscatelli, Guillermo, et al.
Publicado: (2019)

Urban Chagas disease in children and women in primary care centres in Buenos Aires, Argentina
por: Moscatelli, Guillermo, et al.
Publicado: (2015)

Abdominal Cystic Echinococcosis Treated with Albendazole. A Pediatric Cohort Study
por: Moroni, Samanta, et al.
Publicado: (2016)

Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease
por: Stass, Heino, et al.
Publicado: (2020)

Diagnostic Accuracy of Two Molecular Tools for Diagnosis of Congenital Chagas Disease
por: Bisio, Margarita María Catalina, et al.
Publicado: (2021)

Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
por: Forsyth, Colin J., et al.
Publicado: (2016)

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

Follow-up of an Asymptomatic Chagas Disease Population of Children after Treatment with Nifurtimox (Lampit) in a Sylvatic Endemic Transmission Area of Colombia
por: Bianchi, Fiorella, et al.
Publicado: (2015)

Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
por: Altcheh, Jaime, et al.
Publicado: (2021)

Population Pharmacokinetic Study of Benznidazole in Pediatric Chagas Disease Suggests Efficacy despite Lower Plasma Concentrations than in Adults
por: Altcheh, Jaime, et al.
Publicado: (2014)

ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment
por: Rivero, Rocio, et al.
Publicado: (2023)

Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment
por: Santamaria, Cynthia, et al.
Publicado: (2014)

Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes
por: El Ghali, Amer, et al.
Publicado: (2023)

Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults
por: Olivera, Mario Javier, et al.
Publicado: (2015)

Detection of Trypanosoma cruzi by PCR in adults with chronic Chagas disease treated with nifurtimox
por: Vergara, Camilo, et al.
Publicado: (2019)

Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment
por: Jackson, Yves, et al.
Publicado: (2013)

Evaluation of the Chagas Western Blot IgG Assay for the Diagnosis of Chagas Disease
por: Brossas, Jean-Yves, et al.
Publicado: (2021)

Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina
por: Vizcaya, David, et al.
Publicado: (2021)

Congenital syphilis in Argentina: Experience in a pediatric hospital
por: Garcia, Luciana Noemí, et al.
Publicado: (2021)

A Retrospective Cohort Analysis Shows that Coadministration of Minocycline with Colistin in Critically Ill Patients Is Associated with Reduced Frequency of Acute Renal Failure
por: Lodise, Thomas P., et al.
Publicado: (2017)

2128. Lack of Congenital Transmission in Infants Born of Female Patients with Chagas Disease who Became Pregnant During a Nifurtimox Study (CHICO and CHICO SECURE Study)
por: Jaime, A L T C H E H, et al.
Publicado: (2022)

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis
por: Li, Hanbin, et al.
Publicado: (2019)

Validation of Apolipoprotein A-1 and Fibronectin Fragments as Markers of Parasitological Cure for Congenital Chagas Disease in Children Treated With Benznidazole
por: Ruiz-Lancheros, Elizabeth, et al.
Publicado: (2018)

Accurate Real-Time PCR Strategy for Monitoring Bloodstream Parasitic Loads in Chagas Disease Patients
por: Duffy, Tomas, et al.
Publicado: (2009)

Congenital Chagas disease: Updated recommendations for prevention, diagnosis, treatment, and follow-up of newborns and siblings, girls, women of childbearing age, and pregnant women
por: Carlier, Yves, et al.
Publicado: (2019)

Association between Antibiotic Exposure and the Risk of Rash in Children with Infectious Mononucleosis: a Multicenter, Retrospective Cohort Study
por: Zhang, Rui, et al.
Publicado: (2023)

Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes
por: Hughes, Derralynn A, et al.
Publicado: (2023)

Nifurtimox Inhibits the Progression of Neuroblastoma in vivo
por: Kong, Eryan, et al.
Publicado: (2019)

Quantification of Immunoglobulin G against Trypanosoma cruzi in Individuals with Chronic Chagas Disease Treated with Nifurtimox and Evaluated in Prolonged Follow-Up
por: Muñoz, Gabriela, et al.
Publicado: (2019)

Short‐Term Efficacy Reliably Predicts Long‐Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model‐Based Meta‐Analysis
por: Wang, Yehong, et al.
Publicado: (2015)

Simvastatin Improves Cardiac Function through Notch 1 Activation in BALB/c Mice with Chronic Chagas Cardiomyopathy
por: Guzmán-Rivera, Daniela, et al.
Publicado: (2020)

Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox
por: Lang, Dieter, et al.
Publicado: (2022)

Benznidazole Therapy Modulates Interferon-γ and M2 Muscarinic Receptor Autoantibody Responses in Trypanosoma cruzi-Infected Children
por: Cutrullis, Romina A., et al.
Publicado: (2011)

Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease
por: Francisco, Amanda Fortes, et al.
Publicado: (2018)

Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease
por: Vilar-Pereira, Glaucia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jrc4i8tp9a2aug67ncftgml4th